These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21605234)

  • 1. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Leblanc KG; Hughes MP; Sheehan DJ
    Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ transplantation and skin cancer: basic problems and new perspectives.
    Hofbauer GF; Bouwes Bavinck JN; Euvrard S
    Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
    Euvrard S; Ulrich C; Lefrancois N
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic strategies for chemoprevention of skin cancers in transplant recipients.
    Kovach BT; Sams HH; Stasko T
    Clin Transplant; 2005 Dec; 19(6):726-34. PubMed ID: 16313317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
    Karia PS; Azzi JR; Heher EC; Hills VM; Schmults CD
    JAMA Dermatol; 2016 May; 152(5):533-40. PubMed ID: 26792250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
    Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Swiss clinical practice guidelines for skin cancer in organ transplant recipients].
    Lapointe AK; Hofbauer G; Anliker M; Arnold A; Binet I; Hunger R; Kempf W; Pascual M; Pelloni F; Serra A; Laffitte E
    Rev Med Suisse; 2010 Apr; 6(246):854-9. PubMed ID: 20455382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
    Kim C; Cheng J; Colegio OR
    Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.
    Schaper-Gerhardt K; Walter A; Schmitz-Rode C; Satzger I; Gutzmer R
    J Dermatol Sci; 2018 Nov; 92(2):172-180. PubMed ID: 30220530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study.
    Harwood CA; Leedham-Green M; Leigh IM; Proby CM
    Arch Dermatol; 2005 Apr; 141(4):456-64. PubMed ID: 15837863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
    Karayannopoulou G; Euvrard S; Kanitakis J
    Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients.
    Durando B; Reichel J
    Dermatol Ther; 2005; 18(1):1-11. PubMed ID: 15842607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach.
    Ritchie SA; Patel MJ; Miller SJ
    Dermatol Surg; 2012 Oct; 38(10):1604-21. PubMed ID: 22646842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing skin malignancy risk in organ transplant recipients.
    Francis S; Berg D
    Skin Therapy Lett; 2013 Jan; 18(1):1-3. PubMed ID: 23474655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunosuppressive drugs and the development of skin cancer after organ transplantation].
    Gjersvik P; Helsing P; Holdaas H; Bergan S
    Tidsskr Nor Laegeforen; 2012 Oct; 132(18):2064-8. PubMed ID: 23038197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin cancer in liver transplant recipients.
    Otley CC; Pittelkow MR
    Liver Transpl; 2000 May; 6(3):253-62. PubMed ID: 10827224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between infections, HLA type and other transplant-related factors and risk of cutaneous squamous cell carcinoma in solid organ transplant recipients.
    Ingvar Å; Ekström Smedby K; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
    Acta Derm Venereol; 2012 Nov; 92(6):609-14. PubMed ID: 22293782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sun protection attitudes and behaviors of solid-organ transplant recipients.
    Robinson JK; Rigel DS
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):610-5. PubMed ID: 15061844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
    Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
    Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.